At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
COCP Cocrystal Pharma, Inc.
Market Closed 05-31 16:00:00 EDT
2.25
-0.11
-4.66%
盘后2.25
+0.000.00%
19:13 EDT
High2.34
Low2.23
Vol5.54K
Open2.29
D1 Closing2.36
Amplitude4.54%
Mkt Cap22.89M
Tradable Cap15.97M
Total Shares10.17M
T/O12.61K
T/O Rate0.08%
Tradable Shares7.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Noble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP)
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.